Clinical Trial of Electroacupuncture in Axial Spondyloarthritis (E-AcuSpA)
E-AcuSpA
A Randomized Controlled Trial of Electroacupuncture in the Management of Patients With Axial Spondyloarthritis in Singapore (E-AcuSpA)
1 other identifier
interventional
100
1 country
1
Brief Summary
Axial spondyloarthritis (AxSpA) is a chronic disease that causes severe disability and poor quality of life. Current treatment options are limited and there are still significant non-responders to current western medications. Manual acupuncture has been shown to reduce pain in patients with AxSpA. There have been reports of electroacupuncture demonstrating more sustained pain relief. Therefore, the investigators aim to determine the clinical effectiveness, safety and cost-effectiveness of electroacupuncture as compared to manual acupuncture for patients with AxSpA through a randomized controlled trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 17, 2020
CompletedFirst Posted
Study publicly available on registry
August 20, 2020
CompletedStudy Start
First participant enrolled
February 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedDecember 26, 2023
December 1, 2023
3.8 years
August 17, 2020
December 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups
Mean difference in BASDAI score between both groups from baseline to weeks 3, 6, 9 and 12. BASDAI score ranges from 0-10, with higher scores indicating higher disease activity.
Week 3, 6, 9, 12
Secondary Outcomes (8)
Mean difference in Bath Ankylosing Spondylitis Functional Index (BASFI) score between both groups
Week 6, 12, 24
Mean difference in Bath Ankylosing Spondylitis Patient Global score (BAS-G) between both groups
Week 6, 12, 24
Mean difference in Assessment of Spondyloarthritis International Society Health Index (ASAS HI) score between both groups
Week 6, 12, 24
Mean difference in Ankylosing Spondylitis Quality of Life (ASQoL) score between both groups
Week 6, 12, 24
Mean difference in EuroQol- 5 Dimension (EQ-5D) score between both groups
Week 6, 12, 24
- +3 more secondary outcomes
Other Outcomes (9)
Mean difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score between both groups
Week 52
Mean difference in Bath Ankylosing Spondylitis Functional Index (BASFI) score between both groups
Week 52
Mean difference in Bath Ankylosing Spondylitis Patient Global score (BAS-G) between both groups
Week 52
- +6 more other outcomes
Study Arms (2)
Electroacupuncture
EXPERIMENTALIn addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
Manual acupuncture
ACTIVE COMPARATORIn addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
Interventions
Manual acupuncture (see procedures below) will be administered first to obtain the "de qi" sensation. After "de qi" is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min. Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms.
After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve "de qi" (a compositional sensation including soreness, numbness, distention and heaviness). Acupoints used will be similar to those mentioned for electroacupuncture (see above).
Eligibility Criteria
You may qualify if:
- Aged 21 years of age or older
- Diagnosed with AxSpA according to the 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria
- Bath AS Disease Activity Index (BASDAI) score ≥4 on a 11-point Numerical Rating Scale (NRS)
- Failed 2 sequential NSAIDs (including cyclooxygenase-2 inhibitor) at maximal tolerated doses for ≥4 weeks in total
- Patients on concomitant biological therapy (e.g. tumour necrosis factor inhibitor therapy, anti-interleukin 17) or non-biologic disease-modifying antirheumatic drugs (DMARDs) (e.g. methotrexate (MTX) or sulfasalazine (SSZ) or leflunomide (LEF)) at study entry must be on the drug for ≥12 weeks and at stable dose for ≥4 weeks prior to randomisation
- Patients taking systemic corticosteroids have to be on stable dose of ≤10mg/day prednisolone or equivalent for at least two weeks before randomisation.
You may not qualify if:
- Pregnant or breastfeeding women
- With bleeding disorders
- With blood-borne communicable diseases (e.g. hepatitis B, hepatitis C, human immunodeficiency virus, etc)
- With implantable electrical device (e.g. pacemaker)
- Suffering from impaired skin sensation or serious skin lesions along the vertebrae
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Singapore General Hospitallead
- Duke-NUS Graduate Medical Schoolcollaborator
- National University of Singaporecollaborator
- Thong Chai Institute of Medical Researchcollaborator
Study Sites (1)
Singapore General Hospital
Singapore, 169608, Singapore
Related Publications (1)
Kwan YH, Fong W, Ang XL, Tan CS, Tai BC, Huang Y, Bilger M, Phang JK, Tan HC, Lee JV, Sun L, Tan CT, Dong BQ, Koh HL, Leung YY, Lui NL, Yeo SI, Ng SC, Fong KY, Thumboo J, Ostbye T. Traditional Chinese medicine (TCM) collaborative care for patients with axial spondyloarthritis (AcuSpA): protocol for a pragmatic randomized controlled trial. Trials. 2019 Jan 14;20(1):46. doi: 10.1186/s13063-018-3117-2.
PMID: 30642381BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Warren Fong
Singapore General Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 17, 2020
First Posted
August 20, 2020
Study Start
February 24, 2021
Primary Completion
December 1, 2024
Study Completion
December 1, 2025
Last Updated
December 26, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share